How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/famprofazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gewodin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gewodin (FAMPROFAZONE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: famprofazone. Area: Other.

phase 2 famprofazone Nuclear receptor subfamily 2 group E member 1 Other Small molecule Live · refreshed every 30 min

Target snapshot

Gewodin (FAMPROFAZONE). Gewodin works by binding to the nuclear receptor subfamily 2 group E member 1, influencing gene expression and cellular processes.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gewodin TARGET	FAMPROFAZONE		phase 2	famprofazone	Nuclear receptor subfamily 2 group E member 1
Inderal	propranolol	Generic (originally ICI/AstraZeneca)	marketed	Non-selective beta-blocker	Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2	1967-11-13
Cialis	Cialis	Ottawa Hospital Research Institute	marketed		Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2
Cialis	tadalafil	Eli Lilly	marketed	Phosphodiesterase 5 Inhibitor [EPC]	Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2038-12-24 — Cialis · 11975006 · Formulation · US
2038-12-24 — Cialis · 12186322 · Formulation · US
2038-12-24 — Cialis · 11382917 · Formulation · US
2038-12-24 — Cialis · 11666576 · Formulation · US

Sponsor landscape (famprofazone class)

· 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gewodin — Competitive Intelligence Brief. https://druglandscape.com/ci/famprofazone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing